257 related articles for article (PubMed ID: 20411170)
1. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
[TBL] [Abstract][Full Text] [Related]
2. Utility of positron emission tomography in sarcomas.
Schuetze SM
Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
[TBL] [Abstract][Full Text] [Related]
3. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
5. Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas.
Rusten E; Rødal J; Revheim ME; Skretting A; Bruland OS; Malinen E
Acta Oncol; 2013 Aug; 52(6):1160-7. PubMed ID: 23198721
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature.
Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S
Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203
[TBL] [Abstract][Full Text] [Related]
7. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
8. Role of PET/PET-CT in the management of sarcomas.
Kumar R; Chauhan A; Vellimana AK; Chawla M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1241-50. PubMed ID: 16925490
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
10. [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].
Schramm N; Schlemmer M; Rist C; Issels R; Reiser MF; Berger F
Radiologe; 2010 Apr; 50(4):339-48. PubMed ID: 20221579
[TBL] [Abstract][Full Text] [Related]
11. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?
Gabriel M; Rubello D
Nucl Med Commun; 2016 Jan; 37(1):3-8. PubMed ID: 26457597
[TBL] [Abstract][Full Text] [Related]
14. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
Tewfik JN; Greene GS
Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
[TBL] [Abstract][Full Text] [Related]
15. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
16. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
17. Synergistic role of simultaneous PET/MRI-MRS in soft tissue sarcoma metabolism imaging.
Zhang X; Chen YL; Lim R; Huang C; Chebib IA; El Fakhri G
Magn Reson Imaging; 2016 Apr; 34(3):276-9. PubMed ID: 26523656
[TBL] [Abstract][Full Text] [Related]
18. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of 18F-FDG PET/CT in the treatment of sarcomas].
Borbély K; Németh Z; Kásler M
Magy Onkol; 2014 Mar; 58(1):24-31. PubMed ID: 24712003
[TBL] [Abstract][Full Text] [Related]
20. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
